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Abstract
BACKGROUND: A few studies in the last several years have shown that metabolomics, the study of metabolites
and small intermediate molecules, may help better understand the breast carcinogenesis. However, breast cancer
is a heterogeneous disease with different subtypes. Additionally, there is a significant racial difference in terms of
breast cancer incidence and mortality. Few, if any, metabolomics studies in breast cancer have considered race
and tumor subtypes in the study design. METHODS: We performed a global metabolomic profiling using mass
spectrometry and samples from 60 breast cancer cases and 60 matched controls. RESULTS: A total of 375 named
metabolites were observed, with 117 metabolites whose levels were significantly different between African
American and Caucasian American women (P < .05 and q < 0.10) and 78 that differed between breast cancer
cases and healthy controls (P < .05 and q < 0.10). Most of those differentiated metabolites belong to amino acids,
fatty acids, and lysolipids. In the pathway-based analysis, we found that plasma levels of many amino acids were
statistically significantly lower in patients with breast cancer, especially those with triple-negative breast cancer,
than healthy controls. However, plasma levels of many FAs related to β-oxidation were statistically significantly
higher in patients with breast cancer than healthy controls, suggesting the possibility of altered FA β-oxidation
in patients with breast cancer. CONCLUSIONS: Because of small sample size, the clinical usage of the metabolites
from this study is unclear. Further validation of those significant metabolites is warranted, especially with the
consideration of racial difference.
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Introduction
Metabolomics is a science that provides a dynamic portrait of meta-
bolic status. Downstream from genomics, transcriptomics, and proteo-
mics, metabolomics assesses end products of the myriad of intercellular
pathways. Because they are end products, metabolites are much more
stable compared to the upstream products, such as mRNAs and pro-
teins [1]. However, the metabolic phenotype is sensitive to genetic
modification, pathophysiological stimuli, pharmaceutical interventions,
and environmental exposures [2–4]. Major changes can be seen even
after minor stimuli. Therefore, metabolites can potentially serve as
indicators of the overall physiological status, such as cancer, as well as
the response to host and environmental stimuli.
Breast cancer is the most common form of cancer in women.
Metabolomics may be valuable in furthering our understanding the
etiology of breast cancer, especially the difference between African
Americans (AAs) and Caucasian Americans (CAs), and among different
tumor subtypes. Breast cancer results from multistep carcinogenesis.
Mounting evidence from cancer cell metabolism demonstrates that
the transforming process from normal to malignant cells is associated
with profound metabolic disturbances [5–7], and individual tumors
Address all correspondence to: Hua Zhao, PhD, Department of Epidemiology, The
University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston,
TX 77030. E-mail: hzhao2@mdanderson.org
1This work was supported by the National Institutes of Health (7R01CA136483 and
7R21CA139201 to H.Z., 5R21CA162218 to S.L. and H.Z., 5R03CA162131 to J.S.
and H.Z., and P30 CA016056 to Roswell Park Cancer Institute) and the Department
of Defense Breast Cancer Program (BC074340 to H.Z.).
2This article refers to supplementary material, which is designated by Table W1 and is
available online at www.transonc.com.
Received 18 September 2013; Revised 22 November 2013; Accepted 22 November 2013
Copyright © 2013 Neoplasia Press, Inc. Open access under CC BY-NC-ND license.
1944-7124/13
DOI 10.1593/tlo.13619
www.transonc.com
Trans la t iona l Onco logy Volume 6 Number 6 December 2013 pp. 757–765 757
rely on complex, dynamic interaction between tumor and host. The
malignant metabolic phenotype and tumor dependence on host form
the biologic rationale underlying the exploration of the evolving field
of metabolomics in breast cancer.
Although the application of metabolomics in breast cancer research
is still at an early stage, a few studies have already been carried out to
explore the possibility of using metabolomic profiles as biomarkers of
early detection, tumor characterization, and clinical outcome predic-
tion [8–14]. Borgan et al. identified a panel of metabolites in breast
tumor tissues, including glucose, myoinositol, and alanine, which can
successfully differentiate subgroups of breast tumors [11]. In another
study by Sitter et al., they found that a panel of metabolites in breast
tumor tissues can discriminate the patients with good prognosis from
the ones with poor prognosis [9]. The metabolite profiles have also
been interrogated in body fluids from patients with breast cancer
and healthy controls, such as serum, urine, and saliva [10,12,13].
For example, Asiago et al. found a panel of 11 metabolites including
choline and tyrosine in serum that can predict 55% of the patients
who have recurrence 13 months before the recurrence was diagnosed
clinically [12].
However, to our knowledge, there has been no study to date exam-
ining the metabolomic profiles in plasma samples with the consider-
ation of race and tumor subtypes in breast cancer. To fill the gap, we
conducted the current study to explore whether metabolomic profiles
could differentiate patients with breast cancer and healthy women,
with the consideration of race (CA vs AA) and tumor receptor status
[triple-negative vs estrogen receptor–positive/progesterone receptor–
positive (ER+/PR+) breast tumors].
Materials and Methods
Study Population
The study was approved by the Institutional Research Board of
Roswell Park Cancer Institute. Anonymized biospecimens and ques-
tionnaire data used were made available through the Roswell Park
Cancer Institute Data Bank and BioRepository (DBBR) [15]. Patients
are enrolled through site-specific clinics before surgery and/or chemo-
therapy, and controls are individuals who are free from cancer and are
visitors or family members of patients. Relationships between patients
and controls are carefully annotated, so that we avoid overmatching
patients to their own family or friends. Written consent is obtained
from every individual before he/she enrolls in the DBBR. The consent
allows DBBR to provide anonymized biospecimens and questionnaire
data for Institutional Research Board–approved protocols (such as this
study) without further consent. Patients and controls are consented to
provide a blood sample and to complete a questionnaire. Blood samples
are drawn in phlebotomy and transferred to the DBBR laboratory.
Following DBBR standard operating procedure, samples are processed
and blood components were stored within 1 hour of collection to min-
imize degradation. Ten milliliters of whole blood was obtained from
each study subject. Plasma was extracted by centrifuging whole blood
at 3000 rpm for 10 minutes at room temperature. All extracted plasma
samples were stored in phased liquid nitrogen. To minimize the effect
of freeze-thaw on metabolites, we only used plasma samples that had
not been previously thawed. In addition, to minimize the potential
effect of fasting/nonfasting, we only used fasting plasma samples. In this
study, a total of 60 women with breast cancer and 60 cancer-free
women were included in the metabolomic profiling analysis.
Metabolomic Analysis
Metabolomic profiling was conducted on plasma samples at Meta-
bolon Inc (Durham, NC) according to the protocol described below.
Sample accessioning. Each sample received was accessioned into a
laboratory information management system (LIMS) and was assigned
by the LIMS a unique identifier that was associated with the original
source identifier only. This identifier was used to track all sample han-
dling, tasks, results, and so on. The samples (and all derived aliquots)
were tracked by LIMS. All portions of any sample were automatically
assigned their own unique identifiers by LIMS when a new task was
created; the relation of these samples was also tracked. All samples
were maintained at 80°C until processed.
Sample preparation. Sample extraction was conducted by using
aqueous methanol, delivered by an automated liquid handler to remove
the protein fraction while allowing maximum recovery of small mole-
cules. The resulting extract was divided into four fractions: one for
analysis by ultra-HPLC tandem mass spectroscopy (UPLC/MS/MS2)
in the positive mode, one for UPLC/MS/MS2 (negative mode), one
for gas chromatography–mass spectrometry (GC-MS), and one for
backup. Samples were placed briefly on a TurboVap (Zymark) to
remove the organic solvent. Each sample was then frozen and dried
under vacuum. Samples were then prepared for the appropriate instru-
ment, either UPLC/MS/MS2 or GC-MS.
Ultra-HPLC tandem mass spectroscopy. The sample extracts des-
tined for UPLC/MS/MS2 positive and negative mode analyses were
reconstituted and analyzed. Briefly, two of the dried extracts were re-
constituted in acidic or basic liquid chromatography (LC)-compatible
solvents, respectively. The acidic reconstituted extract was analyzed
under positive ion optimized MS conditions, and the basic extract
was analyzed by using negative ion MS optimized conditions in two
independent injections by using separate dedicated columns. The
Orbitrap Elite used a heated electrospray ionization source and
Orbitrap mass analyzer operated at 30,000 mass resolution, scanned
80 to 1000 m/z, and alternated between MS and data-dependent
MS2 scans by using dynamic exclusion.
Gas chromatography–mass spectroscopy. The samples destined for
GC-MS analysis were redried under vacuum desiccation for a minimum
of 24 hours before being derivatized under dried nitrogen with the use of
bis-trimethylsilyl triflouroacetamide. The GC column was 5% phenyl,
and the temperature ramp was from 40°C to 300°C in a 16-minute
period. Samples were analyzed on a Thermo-Finnigan Trace DSQ fast
scanning single-quadrupole mass spectrometer by using electron impact
ionization. The instrument was tuned and calibrated for mass resolu-
tion and mass accuracy on a daily basis. The information output from
the raw data files was automatically extracted as discussed below.
Quality assurance/quality control. For quality assurance/quality
control (QC) purposes, additional samples were included with
each day’s analysis. These samples included extracts of a pool of well-
characterized human plasma, extracts of a pool created from a small
aliquot of the experimental samples, and process blanks. QC samples
were spaced evenly among the injections, and all experimental samples
were randomly distributed throughout the run. A selection of QC
compounds was added to every sample for chromatographic align-
ment, including those under test. These compounds were carefully
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chosen so as not to interfere with the measurement of the endoge-
nous compounds.
Data extraction and compound identification. Raw data were
extracted, peak-identified, and QC processed. Briefly, compounds
were identified by comparison of experimental data to the labora-
tory’s authenticated standard library of purified standards or recur-
rent unknown entities. This library contains the retention time/index,
m/z of the intact standard and its fragmentation spectral data (MS2 or
MS/MS), and chromatographic data on all molecules present in the
library. Biochemical identifications were based on three criteria: reten-
tion index within a narrow retention time/index window of the pro-
posed identification, accurate mass match to the library, and the MS/
MS forward and reverse scores between the experimental data and
authentic standards. More than 3000 commercially available purified
standard compounds have been acquired and registered into LIMS
for distribution to both the LC and GC platforms for determination
of their analytic characteristics. A total of 375 named compounds were
identified in our samples. Metabolites were then grouped into eight
mutually exclusive chemical classes (amino acids, carbohydrates, co-
factors and vitamins, energy metabolites, lipids, nucleotide metabolites,
peptides, and xenobiotics) based on the available literature.
Statistical Analysis
Normalized metabolite concentrations were log-transformed. The
missing values were imputed to the minimum of nonmissing values.
Two types of statistical analysis were performed: 1) significance tests
and 2) pathway analysis. 1) Analysis of variance (ANOVA) contrasts
were used to identify metabolites that differed significantly between
experimental groups. A group of metabolites that achieved statistical sig-
nificance (P < .05), as well as those approaching significance (.05 <
P < .10), was identified. Analysis by two-way ANOVA identified meta-
bolites exhibiting significant interaction and main effects for experi-
mental parameters of race and cancer disease status. An estimate of the
false discovery rate (q value) was calculated to take into account the
multiple comparisons that normally occur inmetabolomic-based studies.
A low q value (q < 0.10) is an indication of high confidence in a result.
2) For pathway, we used random forest analyses. Random forests give
an estimate of how well we can classify individuals in a new data set into
each group, in contrast to a t test, which tests whether the unknown
means for two populations are different or not. Random forests create
a set of classification trees based on continual sampling of the experimen-
tal units and compounds. Then, each observation is classified on the basis
of the majority votes from all the classification trees. Statistical analyses
were performed with the program “R” (http://cran.r-project.org/).
Results
The study population included 60 patients with breast cancer and
60 healthy women as controls. Per their cancer status (case vs control),
race (AA vs CA), and receptor status (ER+/PR+ vs triple negative), they
were divided into six groups, namely, C-P: CA breast cancer patients
with ER+/PR+ breast tumors (N = 15), A-P: AA breast cancer patients
with ER+/PR+ breast tumors (N = 15), C-3N: CA breast cancer
patients with triple-negative breast tumors (N = 15), A-3N: AA breast
cancer patients with triple-negative breast tumors (N = 15), C-C:
CA control subjects (N = 36), and A-C: AA control subjects (N =
24). The groups did not differ on age (P = .87), menopausal status
(P = .74), and body mass index (BMI; P = .53).
Following log transformation and imputation with minimum
observed values for each metabolite, a total of 375 named metabo-
lites were included in the analysis. The original data were presented
in Table W1. Overall, plasma levels of metabolites were significantly
different by cancer status, race, and tumor receptor status. Using
two-way ANOVA to explore the impact of race and cancer status,
we observed 117 metabolites whose levels were significantly differ-
ent between AA and CA women (P < .05) and 78 metabolites whose
levels were significantly different between patients with breast
cancer and healthy controls after adjusting for multiple comparisons
Table 1. Summary of Findings among Patients with Breast Cancer and Healthy Controls by Race and Tumor Receptor Status.
ANOVA Contrasts, Race Race and Receptor Status/Disease State
A-C/C-C A-P/C-P A-3N/C-3N A-Cancer/C-Cancer
Total biochemicals, P ≤ .05 70 63 39 81
Biochemicals (↑↓) 18|52 11|52 3|36 8|73
Total biochemicals,
.05 < P < .10
33 20 31 34
Biochemicals (↑↓) 11|22 8|12 5|26 5|29
ANOVA Contrasts,
Receptor Status
ER+/PR+ Triple Negative ER+/PR+/Triple Negative
A-P/A-C C-P/C-C P/C A-3N/A-C C-3N/C-C 3N/C A-P/A-3N C-P/C-3N P/3N
Total biochemicals,
P ≤ .05
45 24 59 47 55 73 31 17 26
Biochemicals (↑↓) 11|34 14|10 25|34 19|28 43|12 42|31 9|22 5|12 7|19
Total biochemicals,
.05 < P < .10
33 23 34 30 26 21 15 20 16
Biochemicals (↑↓) 11|22 11|12 13|21 12|18 18|8 10|11 10|5 4|16 4|12
Two-Way ANOVA,
Race/Disease Status
Race Main Effect Disease Status
Main Effect
Disease Status–Race
Interaction
Total biochemicals, P ≤ .05 117 78 15
Total biochemicals, .05 < P < .10 26 23 16
For paired comparisons, ↑ and red text indicate P < .05 and the mean values are significantly higher for that comparison; ↓ and green text indicate P < .05 and the mean values are significantly lower.
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(P < .05 and q < 0.10; Table 1). Among metabolites that were dif-
ferent between AA and CA women, the dominant metabolic classes
include amino acids [17], fatty acids (FAs) [27], lysolipids [26], and
xanthine metabolism [10]. Figure 1 shows the box plot of six metabo-
lites whose levels were most significantly different between AA and
CA women (both P and q value < 0.001). They are 5-oxoproline,
tetradecanedioate, hexadecanedioate, 1-myristoylglycerophosphocholine,
2-myristoylglycerophosphorcholine, and α-tocopherol. Among metab-
olites that were different between breast cancer cases and healthy
controls, the dominant metabolic classes include amino acids [15],
FAs [23], and lysolipids [19]. Figure 2 shows the box plot of five
metabolites whose levels were most significantly different between
breast cancer cases and healthy controls (P < .001 and q value ranges
from 0.0059 to 0.0131). They are alanine, tyrosine, hexanoylcarnitine,
1-myristoylglycerophosphocholine, and 2-palmitoylglycerophosphocholine*.
In addition, 15 metabolites were observed to have significant inter-
actions between race and cancer status (P < .05), although none of them
reached statistical significance after adjusting for multiple comparisons.
In further stratified analysis by race and cancer status, there were 70
and 81 metabolites whose levels were found to be significantly different
between AA and CA healthy women and between AA and CA breast
cancer cases (P < .05), respectively. Plasma levels of metabolites were
also significantly different by tumor receptor status. We observed 31,
17, and 26metabolites whose levels were significantly different between
A-P and A-3N, C-P and C-3N, and P and 3N (P < .05), respectively.
Pathway-based analysis was performed to explore the significant
metabolic pathways that might be involved in breast carcinogenesis.
Below is the highlight of the most significant findings:
Lower levels of amino acids in patients with breast cancer than healthy
controls. The majority of amino acids identified in this study were
lower in the plasma samples from patients with breast cancer, espe-
cially those with triple-negative breast cancer, than healthy controls.
Table 2 lists 19 amino acids observed in this study.We observed 10 amino
acids whose levels were significantly lower in patients with triple-
negative breast cancer than healthy controls (P < .05), and the dif-
ference remained statistically significant for eight of them even after
adjusting for multiple comparisons (q ≤ 0.10). By comparison, we
did not observe any amino acids whose levels were significantly
higher in patients with triple-negative breast cancer than healthy
controls. Similarly, we observed eight amino acids whose levels were
significantly lower in patients with ER+/PR+ breast cancer than
healthy controls (P ≤ .05), and the difference remained statistically
significant for two amino acids even after adjusting for multiple
comparison (q ≤ 0.10). When stratified by race, the difference
appeared to be more evident in AA than CA study subjects. However,
because of small sample size, the significant difference in both AA and
CA did not remain after adjusting for multiple comparisons.
Higher levels of FAs in patients with breast cancer than healthy controls.
Levels of many FAs were higher in the plasma samples from patients
with breast cancer, especially those with triple-negative breast cancer,
than healthy controls. The most significantly differentiated FA metabo-
lites are listed in Table 3. They include 4 essential FAs, 17 long-chain
FAs, 3 monohydroxy FAs, 4 dicarboxylate acids, and 5 carnitine metab-
olites. Among them, levels of 27 FAs were significantly higher in
patients with triple-negative breast cancer than healthy controls, and
Figure 1. Top 6 metabolites whose levels differed between AA and CA women.
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levels of 17 FAs were significantly higher in patients with ER+/PR+
breast cancer than healthy controls (P < .05). After adjusting for
multiple comparisons, 22 of them remained statistically significant
for triple-negative breast cancer, and 5 of them remained statistically
significant for ER+/PR+ breast cancer (q ≤ 0.10). The higher levels
of dicarboxylates, monohydroxy FAs, and medium-chain acylcarnitines
in patients with breast cancer may suggest altered FA β-oxidation in
patients with breast cancer [16]. When further stratified by race, we
observed that dicarboxylates were significantly higher in the plasma
of C-P and C-3N subjects compared to C-C subjects. For example,
levels of hexadecanedioate, and octadecanedioate were significantly
higher in C-P (fold changes: 1.72 and 1.64) and C-3N (fold changes:
1.71 and 1.72) subjects than C-C subjects after the adjustment of
multiple comparisons. Similar trend was observed for medium-chain
acylcarnitines in both breast cancer tumor subtypes compared to
control subjects.
Patients with triple-negative breast cancer may have a stronger inflam-
mation signature, especially in the Caucasian population. The essential
FAs linoleate (18:2n6), γ-linolenate (18:3n6) [presented as an isobar
with α-linolenate (18:3n3)], and dihomo-linolenate (20:3n3 or n6)
were significantly higher and had an increased trend in the plasma of
triple-negative and ER+/PR+ breast cancer subjects, respectively.
Whereas the changes were independent of race, they were most
profound in CA women (Table 3 and Figure 3). The linoleate metab-
olites 13-HODE + 9-HODE were also significantly higher in C-3N
subjects. Metabolism of these essential FAs can increase the levels of
the inflammation-associated free FA arachidonate (20:4n6), which
was also significantly higher in C-3N subjects and had a nonsignifi-
cant increased trend in A-3N subjects compared to control subjects.
These changes are potentially a result of the increased lipid profile of
CA women with triple-negative breast cancer and could suggest
increased inflammation in C-3N subjects.
Discussion
In this analysis of metabolomic profiles of plasma samples from
60 patients with breast cancer and 60 healthy women, we observed
that metabolomic profiles appeared to be different by race, cancer
status, and breast tumor receptor status. Using the pathway-based
approach, we found that levels of many amino acids were statistically
significantly lower in patients with breast cancer than healthy con-
trols, possibly suggesting the high demand of amino acids in breast
tumor metabolism. However, we found that many FA metabolites
related to FA β-oxidation were significantly higher in breast cancer
cases than healthy controls, indicating overwhelmed FA β-oxidation
in patients with breast cancer. In addition, we found that patients
with triple-negative breast cancer had a stronger inflammation
Figure 2. Top 5 metabolites whose levels differed between breast cancer cases and healthy controls.
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signature, especially in CA women. To our knowledge, this is the
first study to use the global metabolomics analysis to characterize
metabolomic profiles in breast cancer cases and healthy controls by
race, cancer status, and receptor status.
One of the most important findings from this study is the wide-
spread racial difference in plasma levels of metabolites. Racial differ-
ences may not only affect the levels of metabolites but also modify the
associations between metabolites and breast cancer. Racial disparities
Table 3. Comparison of Selected FA Metabolites between Patients with Breast Cancer and Healthy Controls, Stratified by Race and Tumor Receptor Status.
Subpathway Biochemical Name KEGG HMDB A-P/A-C C-P/C-C ER+/PR+/Ctrl A-3N/A-C C-3N/C-C Triple neg/Ctrl
Essential FA Linoleate (18:2n6) C01595 HMDB00673 1.3 1.35 1.3 1.53 1.46 1.47*
Linolenate [α or γ; (18:3n3 or 6)] C06427 HMDB01388 1.39 1.34 1.3 1.7 1.65 1.62*
Dihomo-linolenate (20:3n3 or n6) C03242 HMDB02925 1.06 1.03 1.01 1.27 1.27 1.24*
Docosapentaenoate (n3 DPA; 22:5n3) C16513 HMDB01976 1.29 1.03 1.03 1.7 1.14 1.24*
Long-chain FA Myristate (14:0) C06424 HMDB00806 1.1 1.28 1.17 1.23 1.33 1.27*
Myristoleate (14:1n5) C08322 HMDB02000 1.24 1.6 1.37 1.61 1.41 1.42*
Palmitate (16:0) C00249 HMDB00220 1.28 1.21 1.22 1.35 1.27 1.29*
Palmitoleate (16:1n7) C08362 HMDB03229 1.43 1.52 1.39 1.62 1.43 1.43*
Margarate (17:0) HMDB02259 1.36 1.28 1.29 1.45 1.58 1.5*
10-Heptadecenoate (17:1n7) 1.37 1.48 1.38* 1.51 1.54 1.49*
Stearate (18:0) C01530 HMDB00827 1.2 1.13 1.16 1.26 1.27 1.26*
Oleate (18:1n9) C00712 HMDB00207 1.64 1.44 1.43* 1.85 1.56 1.6*
cis-Vaccenate (18:1n7) C08367 1.31 1.56 1.43 1.3 2.1 1.71
Stearidonate (18:4n3) C16300 HMDB06547 1.21 0.55 0.64 1.5 0.65 0.77
Nonadecanoate (19:0) C16535 HMDB00772 1.06 1.12 1.08 1.25 1.34 1.29*
10-Nonadecenoate (19:1n9) 1.46 1.51 1.43* 1.66 1.68 1.63*
Eicosenoate (20:1n9 or 11) HMDB02231 1.61 1.33 1.37 1.78 1.51 1.56*
Dihomo-linoleate (20:2n6) C16525 1.43 1.29 1.3 1.74 1.6 1.61*
Arachidonate (20:4n6) C00219 HMDB01043 1.01 1.02 1.01 1.08 1.22 1.15
Docosadienoate (22:2n6) C16533 1.31 1.19 1.2 1.37 1.29 1.29
Adrenate (22:4n6) C16527 HMDB02226 1.12 1.16 1.13 1.25 1.34 1.29*
FA, monohydroxy 3-Hydroxyoctanoate – HMDB01954 1.24 1.15 1.21 1.25 2.05 1.66*
3-Hydroxydecanoate HMDB02203 1.15 1.34 1.24 1.27 1.78 1.54*
13-HODE + 9-HODE 0.83 0.94 0.87 0.98 1.28 1.13
FA, dicarboxylate Adipate C06104 HMDB00448 1.09 0.99 1.05 0.96 3.27* 2.14
Tetradecanedioate HMDB00872 0.81 1.44 1.13 0.87 1.48 1.21
Hexadecanedioate HMDB00672 0.97 1.72* 1.34 0.86 1.71* 1.33
Octadecanedioate HMDB00782 1.13 1.64* 1.37 0.74 1.72* 1.25
Carnitine metabolism Acetylcarnitine C02571 HMDB00201 1.16 1.12 1.14 1.07 1.29 1.19
Hexanoylcarnitine C01585 HMDB00705 2.03 1.46 1.73* 2.12 1.36 1.71*
Octanoylcarnitine – – 2.76 1.56 2.09* 3.32 1.33 2.19*
cis-4-Decenoyl carnitine – – 1.72 1.51 1.61 1.69 1.24 1.45
Laurylcarnitine HMDB02250 1.6 1.19 1.32 1.82 1.31 1.48*
For paired comparisons, shaded cells indicate P < .05 (red indicates that the mean values are significantly higher for that comparison; green values are significantly lower). Blue-bolded text indicates .05 <
P < .10.
*Indicates that the association remains statistically significant after adjusting for multiple comparison (q < 0.10).
Table 2. Comparison of Amino Acids between Patients with Breast Cancer and Healthy Controls, Stratified by Race and Tumor Receptor Status.
Biochemical Name KEGG HMDB A-P/A-C C-P/C-C ER+/PR+/Ctrl A-3N/A-C C-3N/C-C Triple neg/Ctrl
Glycine C00037 HMDB00123 0.88 0.95 0.90 0.92 0.91 0.91
Serine C00065 HMDB03406 0.88 0.96 0.92 0.84 0.94 0.89
Threonine C00188 HMDB00167 0.87 0.87 0.89 0.94 0.93 0.94
Asparagine C00152 HMDB00168 0.82 0.85 0.84 0.82 0.82 0.82*
Alanine C00041 HMDB00161 0.74* 0.89 0.82* 0.74 0.85 0.80*
Glutamate C00025 HMDB03339 1.13 0.94 1.05 1.03 0.98 1.01
Glutamine C00064 HMDB00641 0.90 0.98 0.94 0.97 1.02 1.00
Histidine C00135 HMDB00177 0.89 0.87 0.88* 0.86 0.95 0.91*
Lysine C00047 HMDB00182 0.90 0.93 0.91 0.87 0.85 0.86
Tyrosine C00082 HMDB00158 0.89 0.95 0.92 0.80 0.79* 0.80*
Tryptophan C00078 HMDB00929 0.89 1.00 0.94 0.86 0.90 0.88*
Isoleucine C00407 HMDB00172 0.98 0.88 0.93 0.89 0.98 0.94
Leucine C00123 HMDB00687 0.99 0.88 0.94 0.89 0.96 0.93
Valine C00183 HMDB00883 1.01 0.90 0.95 0.93 0.95 0.94
Cysteine C00097 HMDB00574 0.96 0.96 0.93 1.13 0.96 1.01
Methionine C00073 HMDB00696 0.85 0.90 0.88 0.82 0.91 0.87*
Arginine C00062 HMDB00517 0.86 0.92 0.90 0.86 0.85 0.86*
Proline C00148 HMDB00162 0.83 0.87 0.85 0.82 0.92 0.87*
Phenylalanine C00079 HMDB00159 0.92 0.94 0.92 0.87 0.93 0.90
For paired comparisons, shaded cells indicate P < .05 (green indicates that the mean values are significantly lower for that comparison). Blue-bolded text indicates .05 < P < .10.
*Indicates that the association remains statistically significant after adjusting for multiple comparison (q < 0.10).
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in breast cancer are well documented [17–21]. Compared to CA
women, AA women tend to develop more aggressive tumors, charac-
terized by earlier age at diagnosis, higher nuclear grade, higher mitotic
index, and lower prevalence of ER and/or PR expression, and sub-
sequently have poorer survival. Genetic susceptibility has been sug-
gested to play a role in the racial/ethnic disparity of breast cancer
[20,22,23]. However, currently known genetic factors explain only a
small fraction of the heritability for breast cancer. A substantial pro-
portion of the observed racial/ethnic disparity remains unexplained.
Additionally, most of the genetic variants identified so far are located
in non–protein-encoding regions with undetermined biologic func-
tional significance. Thus, alternative approaches are critically needed
to provide new insight to biologic function and carcinogenesis. There-
fore, studies focusing on metabolic profiles may prove to be a useful
alternative approach. Interestingly, a recent study by Gieger et al. found
that up to 12% of the observed variance in the metabolic homeostasis
of the human body could be explained by genetic variants [24]. There-
fore, the results from this study may help elucidate the racial difference
in genetic susceptibility to breast cancer.
Tocopherols are a class of biochemicals that have different antioxidant
properties dependent on the tocopherol isoform [25]. α-Tocopherol is
believed to be the main source found in supplements and in the
European diet, whereas γ-tocopherol is the most common form in the
American diet. α-Tocopherol is the form of vitamin E that is prefer-
entially absorbed and accumulated in humans. In this study, we found
the levels of α-tocopherol were statistically significantly higher in CA
than AA women (Figure 1). Meanwhile, the levels of γ-tocopherol were
statistically significantly lower in CA than AA women (data not shown).
Those observations suggest a race-dependent disparity in tocopherol
isomers. Furthermore, C-3N subjects had significantly higher levels of
γ-tocopherol and a nonsignificant decreased trend in α-tocopherol
compared to C-C or C-P subjects. This finding may indicate an asso-
ciation among higher γ-tocopherol levels, lower α-tocopherol levels,
and triple-negative breast cancer and may provide a hint for why AAs
have a higher incidence of triple-negative breast cancer.
The majority of amino acids identified in this study were lower in
the plasma from patients with breast cancer, especially those with triple-
negative breast cancer. This observation is consistent with the roles of
amino acids in carcinogenesis. Various studies have shown that the
availability of circulating amino acids is often reduced in patients with
cancer [26–28]. The reduced availability is caused by the malnutrition
in a tumor-bearing state and by an increase in the amino acid demand
as a consequence of the presence of the tumor. However, no con-
sistent cancer-specific amino acid has emerged. Increased or decreased
levels of different amino acids in blood have been reported in breast
cancer [29–31]. For example, tyrosine was reported to decrease in
the blood of different kinds of cancer including breast cancer [26].
Reports about alanine and asparagine in the plasma of patients with
breast cancer are inconsistent, with both increased and decreased plasma
levels reported [26,28,30,32]. Heber suggested that decreased Ala
in plasma of patients with cancer is due to the increased alanine flux
for gluconeogenesis [26].
In addition, different types of FAs are found to be different between
breast cancer cases and healthy controls, including essential FAs, long-
chain FAs, monohydroxy FAs, dicarboxylate acids, and carnitine metab-
olites. Elevated levels of FAs, either from the cancer cell or exogenous fat
sources, have been suggested to promote more aggressive tumorigenic
phenotype [33]. Both epidemiological and animal studies have suggested
an association between dietary FAs, obesity, and an increased risk of
breast cancer [34,35]. Free FAs mediate cell proliferation, extracellular
signal-regulated protein kinases 1 and 2 (ERK1/2) activation, and other
biologic effects in breast cancer cells, and FA accumulation may induce
mitochondrial dysfunction, increased ROS production, inflammation,
and so on [36]. This is consistent with our findings in this study. For
example, oleic acid, which had significantly higher levels in patients
with triple-negative breast cancer than healthy controls, is reported to
induce proliferation, migration, prolong survival, invasion, mitogen-
activated protein kinase/extracellular signal-regulated kinase (ERK)
kinase 1/2 (MEK1/2), ERK1/2, and Src/focal endocrine kinases (FAK)
activation in breast cancer cells [37]. n-6 polyunsaturated FAs have
been reported to promote inflammation and carcinogenesis by influenc-
ing the properties of cancer and host cells [38]. Linolenic acid and linoleic
acid, both belonging to n-6 polyunsaturated FAs, are also increased in
patients with triple-negative breast cancer in our study. Evidence sug-
gests that linolenic acid may influence the proliferation, differentiation,
and prognosis of breast cancer [39], and genes involved in the regulation
Figure 3. Subjects with triple-negative breast cancer have a stronger inflammation signature, especially in the CA women.
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of linolenic acid metabolism were associated with breast cancer risk in a
genome-wide association study of breast cancer [40].
In order for long-chain FAs to cross the mitochondrial matrix for
FA β-oxidation, they must be conjugated to carnitine forming long-
chain acylcarnitines (e.g., laurylcarnitine and oleoylcarnitine). Thus,
the significantly higher levels of long-chain FAs and long-chain acyl-
carnitines observed in breast cancer plasma regardless of breast tumor
subtype and race could indicate either decreased liver FA β-oxidation
or possibly overwhelmed β-oxidation. One of the by-products released
by the liver during FA β-oxidation is the ketone body 3-hydroxybutyrate
(BHBA), which is increased in patients with triple-negative breast
cancer in our study. BHBA is a well-established marker of mitochon-
drial dysfunction. The significantly higher BHBA in patients with
breast cancer suggests that FA β-oxidation is occurring at a high rate
in breast cancer subjects.
A major limitation of this study is that the biospecimens from breast
cancer cases were not collected before diagnosis, which will limit our
ability to infer causations between metabolites and breast cancer. The
relevance of a plasma measure to tissue activity is also a potential con-
cern. One study found similar changes in metabolomic profiles as a
result of exercise in muscle biopsies and plasma [41], suggesting the
validity of using plasma as the surrogate tissue. One more concern is
the representativeness of a single plasma sample to reflect long-term
levels. Nevertheless, our study provides evidence that metabolomic
profiles differ by race, cancer status, and breast tumor receptor status.
Because of small sample size, we will not be able to draw a conclusion
on the clinical usage of those identified metabolites. Clearly, they need
to be further vigorously validated in sequential samples collected from
large and prospective multi-ethnic populations.
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